Merck (MRK) has a done a lot right in cancer immunotherapy, probably more than any of its pharma rivals. But the clinical debut of a new immune-boosting drug from its early-stage cancer pipeline Saturday suggests Merck is not heeding a hard lesson learned from its biggest blunder.

The new Merck drug, called MK-1454, shows no evidence that it can kill cancer cells when injected into patients on its own, as a monotherapy. But when MK-1454 was used in combination with Merck’s checkpoint inhibitor Keytruda, the tumors in a small number of patients got smaller.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy